aTyr Pharma Inc. (LIFE)
NASDAQ: LIFE
· Real-Time Price · USD
1.90
0.05 (2.70%)
At close: Jun 04, 2024, 10:00 PM
aTyr Pharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | -4.67M | n/a | n/a | 235K | 4.32M | 353K | n/a | n/a | 10.39M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 2.17M | n/a | n/a | 770K | 407K | 993K | 586K | 755K | 697K | 414K | 286K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | -2.73M | n/a | n/a | 66K | 3.91M | -640K | -586K | -755K | 9.69M | -414K | -286K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -15.77M | -22.7M | -18.14M | -17.32M | -16.64M | -15.96M | -12.62M | -13.56M | -12.79M | -7.95M | -13.49M | -12.58M | -12.38M | -8.64M | -7.73M | -10.45M | -7.2M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -14.88M | -22.43M | -17.26M | -16.31M | -15.49M | -14.76M | -11.34M | -12.34M | -11.95M | -7.52M | -13.24M | -12.42M | -12.15M | -8.56M | -7.67M | -10.39M | -7.16M |
Net Income | -14.88M | -22.43M | -17.26M | -16.31M | -15.49M | -14.76M | -11.34M | -12.34M | -11.12M | -7.09M | -13M | -12.26M | -11.93M | -8.56M | -7.67M | -10.39M | -7.15M |
Selling & General & Admin | 3.96M | 5.59M | 3.34M | 3.34M | 3.51M | 3.2M | 2.65M | 3.72M | 3.41M | 3.43M | 3.63M | 3.45M | 3.48M | 2.69M | 2.59M | 2.79M | 2.69M |
Research & Development | 11.81M | 17.93M | 14.81M | 13.97M | 13.36M | 12.76M | 10.32M | 9.84M | 9.38M | 14.91M | 9.87M | 9.13M | 8.9M | 5.96M | 5.14M | 7.66M | 4.52M |
Other Expenses | n/a | n/a | n/a | n/a | 1.15M | 1.2M | 1.27M | 1.22M | 835K | 427K | 247K | 163K | n/a | 79K | 59K | 53K | 47K |
Operating Expenses | 15.77M | 23.53M | 18.14M | 17.32M | 16.87M | 15.96M | 12.97M | 13.56M | 12.79M | 18.34M | 13.49M | 12.58M | 12.38M | 8.64M | 7.73M | 10.45M | 7.2M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 1.18M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 25.7M | n/a | n/a | 16.87M | 15.96M | 12.97M | 13.56M | 12.79M | 18.34M | 13.49M | 12.58M | 12.38M | 8.64M | 7.73M | 10.45M | 7.2M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -1K | n/a | -4K | -836K | -429K | -248K | -164K | -225K | 7K | -331K | -1K | -301K |
Shares Outstanding (Basic) | 75.8M | 75.8M | 75.8M | 72.28M | 66.08M | 59.26M | 57.89M | 55.14M | 41.9M | 29.12M | 28.66M | 28.06M | 27.82M | 27.78M | 18.16M | 16.13M | 14.1M |
Shares Outstanding (Diluted) | 75.8M | 75.8M | 75.8M | 72.28M | 66.08M | 59.26M | 57.89M | 55.14M | 41.9M | 29.12M | 28.66M | 28.06M | 27.82M | 27.79M | 18.16M | 16.13M | 14.1M |
EPS (Basic) | -0.2 | -0.3 | -0.23 | -0.23 | -0.23 | -0.25 | -0.2 | -0.22 | -0.27 | -0.24 | -0.45 | -0.44 | -0.43 | -0.31 | -0.42 | -0.64 | -0.51 |
EPS (Diluted) | -0.2 | -0.3 | -0.23 | -0.23 | -0.23 | -0.25 | -0.2 | -0.22 | -0.27 | -0.24 | -0.45 | -0.44 | -0.43 | -0.31 | -0.42 | -0.64 | -0.51 |
EBITDA | -14.88M | -22.43M | -17.26M | -16.31M | -15.87M | -15.55M | -12.62M | -12.97M | -12.03M | -7.95M | -13.49M | -12.3M | -12.08M | -8.64M | -7.73M | -10.09M | -7.2M |
EBIT | -14.88M | -22.43M | -17.26M | -16.31M | -16.64M | -13.93M | n/a | -13.56M | -12.79M | -8.22M | -13.66M | -12.58M | -12.38M | n/a | n/a | -10.45M | n/a |
Depreciation & Amortization | n/a | n/a | n/a | n/a | 770K | 407K | 993K | 586K | 755K | 697K | 414K | 286K | 298K | 320K | 329K | 358K | 297K |